On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation

The oral direct thrombin inhibitor dabigatran is increasingly used to prevent thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is currently not recommended, but measurements of dabigatran and/or its effect are desirable in certain situations. We studied dabigatran exposure and compared different tests for monitoring of dabigatran in a real-life cohort of AF patients.

Source: Thrombosis Research - July 6, 2014 Category: Hematology Authors: Mika Skeppholm, Paul Hjemdahl, Jovan P. Antovic, Josephine Muhrbeck, Jaak Eintrei, Yuko Rönquist-Nii, Anton Pohanka, Olof Beck, Rickard E. Malmström Tags: Regular Article Source Type: research